 Remission Induction
"Remission Induction" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Therapeutic act or process that initiates a response to a complete or partial remission level.
| Descriptor ID |
D012074
|
| MeSH Number(s) |
E02.860
|
| Concept/Terms |
Remission Induction- Remission Induction
- Induction, Remission
- Inductions, Remission
- Induction of Remission
- Remission Inductions
|
Below are MeSH descriptors whose meaning is more general than "Remission Induction".
Below are MeSH descriptors whose meaning is more specific than "Remission Induction".
This graph shows the total number of publications written about "Remission Induction" by people in this website by year, and whether "Remission Induction" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 3 | 3 | | 1994 | 0 | 5 | 5 | | 1995 | 0 | 7 | 7 | | 1996 | 0 | 1 | 1 | | 1997 | 0 | 3 | 3 | | 1998 | 0 | 2 | 2 | | 1999 | 0 | 3 | 3 | | 2000 | 0 | 3 | 3 | | 2001 | 0 | 5 | 5 | | 2002 | 0 | 2 | 2 | | 2003 | 0 | 2 | 2 | | 2004 | 1 | 4 | 5 | | 2005 | 0 | 2 | 2 | | 2006 | 0 | 1 | 1 | | 2007 | 0 | 2 | 2 | | 2008 | 0 | 9 | 9 | | 2009 | 0 | 12 | 12 | | 2010 | 0 | 9 | 9 | | 2011 | 0 | 9 | 9 | | 2012 | 2 | 8 | 10 | | 2013 | 0 | 13 | 13 | | 2014 | 0 | 12 | 12 | | 2015 | 0 | 7 | 7 | | 2016 | 0 | 6 | 6 | | 2017 | 0 | 9 | 9 | | 2018 | 0 | 16 | 16 | | 2019 | 1 | 13 | 14 | | 2020 | 0 | 10 | 10 | | 2021 | 0 | 8 | 8 | | 2022 | 0 | 6 | 6 | | 2023 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Remission Induction" by people in Profiles.
-
Galletta TJ, Rubinstein JD, Krupski C, Nelson AS, Khoury R, Dandoy CE, Davies SM, Phillips CL. Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel. Pediatr Blood Cancer. 2023 05; 70(5):e30271.
-
Johnson AM, Barsky M, Ahmed W, Zullow S, Galati J, Jairath V, Narula N, Peerani F, Click BH, Coburn ES, Dang TT, Gold S, Agrawal M, Garg R, Aggarwal M, Mohammad D, Halloran B, Kochhar GS, Todorowski H, Ud Din NM, Izanec J, Teeple A, Gasink C, Muser E, Ding Z, Swaminath A, Lakhani K, Hogan D, Datta S, Ungaro RC, Boland BS, Bohm M, Fischer M, Sagi S, Afzali A, Ullman T, Lawlor G, Baumgart DC, Chang S, Hudesman D, Lukin D, Scherl EJ, Colombel JF, Sands BE, Siegel CA, Regueiro M, Sandborn WJ, Bruining D, Kane S, Loftus EV, Dulai PS. The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium. Am J Gastroenterol. 2023 02 01; 118(2):317-328.
-
Oslin DW, Lynch KG, Shih MC, Ingram EP, Wray LO, Chapman SR, Kranzler HR, Gelernter J, Pyne JM, Stone A, DuVall SL, Lehmann LS, Thase ME, Aslam M, Batki SL, Bjork JM, Blow FC, Brenner LA, Chen P, Desai S, Dieperink EW, Fears SC, Fuller MA, Goodman CS, Graham DP, Haas GL, Hamner MB, Helstrom AW, Hurley RA, Icardi MS, Jurjus GJ, Kilbourne AM, Kreyenbuhl J, Lache DJ, Lieske SP, Lynch JA, Meyer LJ, Montalvo C, Muralidhar S, Ostacher MJ, Paschall GY, Pfeiffer PN, Prieto S, Przygodzki RM, Ranganathan M, Rodriguez-Suarez MM, Roggenkamp H, Schichman SA, Schneeweis JS, Simonetti JA, Steinhauer SR, Suppes T, Umbert MA, Vassy JL, Voora D, Wiechers IR, Wood AE. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. JAMA. 2022 07 12; 328(2):151-161.
-
Laetsch TW, Maude SL, Balduzzi A, Rives S, Bittencourt H, Boyer MW, Buechner J, De Moerloose B, Qayed M, Phillips CL, Pulsipher MA, Hiramatsu H, Tiwari R, Grupp SA. Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia. Leukemia. 2022 06; 36(6):1508-1515.
-
Baker JF, England BR, George MD, Wysham K, Johnson T, Lenert A, Kunkel G, Sauer B, Duryee MJ, Monach P, Kerr G, Reimold A, Thiele GM, Mikuls TR. Adipocytokines and achievement of low disease activity in rheumatoid arthritis. Semin Arthritis Rheum. 2022 08; 55:152003.
-
Cannon LA, Wenderfer SE, Lewandowski LB, Cooper JC, Goilav B, Knight AM, Hersh AO, Ardoin SP, Sadun RE. Use of EuroLupus Cyclophosphamide Dosing for the Treatment of Lupus Nephritis in Childhood-onset Systemic Lupus Erythematosus in North America. J Rheumatol. 2022 06; 49(6):607-614.
-
O'Brien MM, Ji L, Shah NN, Rheingold SR, Bhojwani D, Yuan CM, Xu X, Yi JS, Harris AC, Brown PA, Borowitz MJ, Militano O, Kairalla J, Devidas M, Raetz EA, Gore L, Loh ML. Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. J Clin Oncol. 2022 03 20; 40(9):956-967.
-
Ahmed W, Lukin DJ. A step towards informed positioning of advanced therapies for moderate-to-severe Crohn's disease. Lancet Gastroenterol Hepatol. 2021 12; 6(12):973-975.
-
Inamo J, Suzuki K, Takeshita M, Kondo Y, Okuzono Y, Koga K, Kassai Y, Takiguchi M, Kurisu R, Yoshimura A, Takeuchi T. Molecular remission at T cell level in patients with rheumatoid arthritis. Sci Rep. 2021 08 17; 11(1):16691.
-
Garg R, Aggarwal M, Butler R, Achkar JP, Lashner B, Philpott J, Cohen B, Qazi T, Rieder F, Regueiro M, Click B. Real-World Effectiveness and Safety of Ustekinumab in Elderly Crohn's Disease Patients. Dig Dis Sci. 2022 07; 67(7):3138-3147.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|